LeMaitre Vascular delivered strong Q2 results with 15% sales growth, robust margins, and increased dividends. Click here to read LMAT stock's buy thesis.
LeMaitre Vascular: Investment Debate Remains In Place (NASDAQ:LMAT)
Seeking Alpha Stock2 hrs ago
15
CBS News
America News
Raw Story
CNN Business
New York Post
Cover Media
Martinsburg Journal
Essentiallysports Football